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Bacterial scissors to edit human embryos?
A recently discovered gene editing tool raises the possibility of precisely targeted 
changes to human genes, even in the germline. The nascent debate over the 
ethics and limitations of its use has already been overtaken by events. Is this a 
whole new Pandora’s box for bioethics? Michael Gross investigates. Dividing issue: The invention of easy-to-use genome editing tools has brought the promise of 
medical breakthroughs and fears of manipulations in the human germline. Lasting changes could 
be made in the fertilized egg or in early stage embryos like the one shown here. (Image: Dr Yorgos 
Nikas/Science Photo Library.)Gene therapy has recently made 
a surprising comeback due to the 
emergence of better vectors and editing 
tools (Curr. Biol. (2014) 24, 983–986). 
The most revolutionary new tool in the kit 
of gene therapists is Cas9, the CRISPR-
associated nuclease. Only recently 
discovered as part of an unexpected 
adaptive immune response in bacteria, 
this nuclease can be programmed to 
edit any target sequence. It opens up 
opportunities to edit human genes — 
in somatic cells and indeed in the 
germline — with unprecedented ease 
and simplicity. With these new powers 
come new responsibilities for scientists, 
and new debates over bioethics. 
The bacterial immune system 
Much of what we now know about the 
CRISPR (clustered regularly interspaced 
short palindromic repeats) system goes 
back to a collaboration between the 
groups of Jennifer Doudna at Berkeley, 
USA, and Emmanuelle Charpentier at 
Umea, Sweden, which started only in 
2011, but has already been awarded 
with prestigious prizes. Both groups 
had independently noticed that bacterial 
strains seem to have a kind of memory 
for phages that have attacked them in 
the past, and together they identified the 
nuclease Cas9 as the crucial tool that 
cuts the viral genome. 
When bacteria have overcome 
a viral infection, they incorporate 
certain parts of the viral genes into the 
CRISPR region of their own genome 
as so-called spacers. These spacers 
are transcribed as RNAs, which then 
bind to the nuclease Cas9 and guide 
it to any intact DNA containing the 
very same sequence. Using additional 
criteria, the Cas9–RNA complex can 
recognise if the DNA is foreign (i.e. 
viral) and then cleave it to inactivate 
the virus. This completely unexpected 
system is a microbial analogue of our 
adaptive immune system, using RNA 
recognition rather than antibodies to 
identify known adversaries. During the course of these sensational 
discoveries, the groups realised that 
the target recognition system, based 
on two separate strands of RNA, could 
be simplified if these strands were 
combined into a single, longer strand. 
This trick generated the new gene editing 
tool which turned out to be usable on 
just about any living cell imaginable. As 
geneticist Marie-Claire King wrote for 
Time magazine’s list of 100 pioneers, 
“Emmanuelle Charpentier and Jennifer 
Doudna figured out the inner workings of 
this bacterial self-protection, and then, in 
a tour de force of elegant deduction and 
experiment, they developed a plug-and-
play version of that approach.” Current Biology 25, R439–R447, June 1, 2015 ©The most recent improvement to the 
tool features a smaller version of the 
enzyme discovered in Staphylococcus 
aureus. Its gene is small enough to 
be delivered into cells with adeno-
associated virus (AAV), currently the most 
widely used vector for gene therapy 
research (Nature (2015) 520, 186–191). 
Meanwhile, investigations on the 
natural function of the CRISPR system 
continue, as new and fascinating details 
of the bacterial immune system emerge, 
which also includes a whole range 
of other Cas proteins. The functional 
complex of these proteins with their 
guiding RNA molecules is also known 
as the Cascade complex. This comes in 
three different types, and two research 
teams have reported crystal structures of 
a type I complex with or without its target 
sequence (Science (2014) 345, 1479–
1484 and 1473–1479, respectively).
Only recently, Doudna’s team could 
report an in vitro version of the E. coli 
system demonstrating that the proteins 
Cas1 and Cas2 are sufficient for the 
process of integrating the viral sequences 2015 Elsevier Ltd All rights reserved R439
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Prizeworthy: Jennifer Doudna and Emmanuelle Charpentier identified the nuclease Cas9 as a key 
part of the bacterial immune response to phages and adapted it for use as a universally applicable 
genome editing tool. (Photo: Justin Bishop/Breakthrough Prize http://www.breakthroughprize.org.)into the bacterial genome (Nature (2015) 
519, 193–198). In the same journal issue, 
the groups of David Bikard at the Institut 
Pasteur in Paris and Luciano Marraffini 
at Rockefeller University in New York, 
showed that Cas9 in Streptococus 
pyogenes not only acts as a nuclease, 
but also associates with Cas1 and Cas2 
in the initial selection stage, where it 
ensures that the protospacers selected 
for the immunological memory formation 
are flanked by suitable protospacer 
adjacent motifs (PAMs), a pair of guanine 
bases just downstream of the target 
sequence (Nature (2015) 519, 199–202). 
Addressing the question of how the 
system manages to avoid the bacterial 
equivalent of autoimmune disease, i.e. 
attacking its own DNA, the groups of 
Udi Qimron at Tel Aviv University and 
Rotem Sorek at the Weizmann Institute, 
both Israel, found that the harvesting 
of spacers from viral DNA primarily 
targets DNA in replication. A number 
of factors, including the higher number 
of replication forks in viral DNA, the 
higher density of Chi sites in bacterial 
DNA, and the activity of the RecBCD 
double strand repair system all play a 
role in the avoidance of an autoimmune 
response (Nature (2015) 520, 505–510).
Further work from Doudna’s group 
has revealed the structure of a type 
III CRISPR complex that targets 
single-stranded viral RNA rather than R440 Current Biology 25, R439–R447, Junedouble-stranded DNA. Similarities 
between this complex and the known type 
I complex suggest that both evolved 
from a common ancestor (Science (2015) 
348, 581–585). More recent research from 
the Marraffini lab suggests that type III 
complexes can target both RNA and DNA 
(Cell (2015) http://dx.doi.org/10.1016/j.
cell.2015.04.027). High-profile publications 
addressing fundamental questions of 
the bacterial immune system are still 
appearing regularly, showing that our 
understanding of this recently discovered 
phenomenon is still in flux. In the 
meantime, its revolutionary application in 
biomedical science is gathering pace. 
Somatic gene repair
By combining this RNA-guided gene-
editing tool with the desired repair 
templates, the well-directed cut can 
enable deletions, replacements or 
insertions of genetic material. In principle, 
the technique could alter germline cells 
and thus the genetic make-up of future 
generations, as well as somatic cells, 
where it will only affect the present 
patient treated. 
Somatic gene repair is less 
questionable on ethical grounds but 
still has its safety issues. When genetic 
material has to be introduced into many 
cells at once, there is always the risk 
that some of it may end up in the wrong 
place and cause side effects. (In this  1, 2015 ©2015 Elsevier Ltd All rights reservedrespect, the somatic editing can be more 
challenging than germline editing, which 
could be included in the fertilisation step.) 
The first targets for somatic editing are 
therefore likely to be blood cells, which 
can easily be taken, treated and returned. 
One approach currently undergoing 
clinical trials is to inactivate the receptor 
to which HIV docks — an idea inspired 
by the rare patients who are naturally 
resistant to HIV. The hope is to free 
patients of the need to take antiretroviral 
drugs. The company Sangamo 
BioSciences at Richmond, California, 
currently tests such a therapy with the 
older zinc finger nuclease technology, 
but it could also point the way for similar 
applications of CRISPR nucleases, which 
could be much more rapidly adapted to 
new targets. 
Other conditions that could be treated 
in similar ways include b thalassaemia, 
sickle cell anaemia, haemophilia, 
Huntington’s disease and SCID (severe 
combined immunodeficiency) — the 
condition that was the target of early 
attempts at gene therapy in the 1990s. 
The CRISPR–Cas system also 
promises better control in the study of 
disease states in stem-cell-derived in 
vitro systems. So far, such studies have 
been hindered by confounding genetic 
variability. However, CRISPR now 
enables researchers to very precisely 
repair the particular mutations thought to 
be involved in order to create so-called 
isogenic cell lines that are genetically 
identical to their diseased counterparts 
at every locus except the putative 
causative gene, as Paul Fairchild, 
co-director of the Oxford Stem Cell 
Institute at the University of Oxford, UK, 
points out. Experiments linking specific 
gene repairs to amelioration of disease 
states could bring unequivocal proof 
of causation. “There is little doubt that 
combining powerful technologies such 
as CRISPR and induced pluripotency will 
greatly accelerate our understanding of 
the genetic basis of disease processes 
that have remained intractable for 
decades,” Fairchild comments. 
Germline operations
The envisioned manipulations of somatic 
cells and in vitro cell cultures may not 
raise many concerns at the current state 
of bioethical debates. What did cause a 
big stir, however, was the more troubling 
possibility that the new editing tool might 
be applied to the germline and thus 
Current Biology
Magazine
180°
Cas9 protein
sgRNA
Complementary DNA strand
Non-complementary DNA strand
PAM
Current Biology
Bacterial scissors: Cas9, the enzyme at the heart of the CRISPR gene editing system, uses a 
strand of RNA to identify the target site. As this RNA can be readily exchanged, Cas9 can be 
targeted to any location in a genome. (Image: Anders et al. (2014). Structural basis of PAM-de-
pendent target DNA recognition by the Cas9 endonuclease. Nature 513, 569–573, http://dx.doi.
org/10.1038/nature13579.)alter the genes of future generations. 
Germline manipulation has been a 
fundamental taboo so far — but one that 
was easily policed as long as there was 
no promising technology with which to 
manipulate the germline. 
Now the situation is entirely different. 
The technology that might one day lead 
to designer babies as envisioned in the 
film GATTACA is on the table, and it will 
be impossible to uninvent it. A small 
door towards germline manipulation 
was already opened in February 2015, 
when the UK, as the first country in the 
world, legislated to allow the use of 
mitochondrial replacement. The law will 
come into force in October, by which 
time the regulatory body, the Human 
Fertilisation and Embryo Authority 
(HFEA), will draw up detailed procedures 
regarding how it will regulate the 
application of the new technique. 
Rumours of several research papers 
applying CRISPR editing to human 
embryos were circulating early this year, 
prompting the International Society for 
Stem Cell Research (ISSCR) and two 
informal groups of experts to voice their 
concern and call for moratoria and a 
wider debate on the fundamental ethical 
aspects.  
On March 19th, the ISCCR called for “a 
moratorium on attempts to apply nuclear 
genome editing of the human germline 
in clinical practice. Scientists currently 
lack an adequate understanding of the 
safety and potential long term risks of 
germline genome modification.” Further, 
the organisation asserted “that a deeper 
and more rigorous deliberation on the 
ethical, legal and societal implications 
of any attempts at modifying the human 
germline is essential if its clinical practice 
is ever to be sanctioned.”
A week later, Edward Lanphier, the 
president and chief executive of the 
above-mentioned company Sangamo 
BioSciences, and others published a 
comment in Nature asking researchers 
to abstain from editing the human 
germline (Nature (2015) 519, 410–411). 
The authors argued that all genuine 
medical needs are better served by other 
approaches, such as prenatal genetic 
diagnostics and IVF. After acknowledging 
the spectacular impact of CRISPR 
on gene editing, they wrote: “But we 
cannot imagine a situation in which its 
use in human embryos would offer a 
therapeutic benefit over existing and 
developing methods.”The authors expressed their concern 
that a bioethics backlash against the 
use of germline editing might harm the 
prospects of other forms of gene therapy 
that are currently under development 
and appear much more promising. 
“Legitimate concerns regarding the safety 
and ethical impacts of germline editing 
must not impede the significant progress 
being made in the clinical development 
of approaches to potentially cure serious 
debilitating diseases,” Lanphier and 
colleagues concluded. 
A separate statement was published 
a week later by a group of experts who 
met at Napa, California, in January, 
including Jennifer Doudna, George 
Church, and David Baltimore (Science 
(2015) 348, 36–38). This comment, under 
the title “A prudent path forward for 
genomic engineering and germline gene 
modification” calls for a moratorium on 
germline modification while safety and 
ethical concerns are being discussed, but 
does not rule out its use at a later stage. 
The authors called for further research 
to address questions like the likelihood 
of off-target modifications and the 
physiological effects in cells after gene 
editing. They recommended to “strongly 
discourage, even in the countries with lax 
jurisdictions where it might be permitted, 
any attempts at germline genome 
modification for clinical application in 
humans, while societal, environmental, 
and ethical implications of such activity Current Biology 25, R439–R447, June 1, 2015 ©are discussed among scientific and 
governmental organizations.” However, 
this group left the door open for scientists 
to embark on germline modification in the 
future, if safety, transparency, and public 
trust can be maintained. 
Only two weeks later, the rumours 
were confirmed when the groups of 
Canquan Zhou and Junjiu Huang at Sun 
Yat-sen University in Guangzhou, China, 
published the first report of germline 
editing in human embryos (Protein Cell 
(2015) 6, 363–372). In an attempt to 
score their first without being vilified for 
transgression of ethical boundaries, the 
researchers used tripronuclear zygotes 
for their experiments. These result 
when an egg is fertilised by two sperms 
simultaneously. They are not viable and 
would normally be discarded in IVF 
clinics. Thus, their manipulations only 
affect a dead end of the germline and 
could under no circumstances end up 
affecting live human beings. 
That said, the experiments aimed at 
the gene involved in b thalassaemia, so 
they were clearly conducted with the 
ultimate ambition of medical applications. 
The results of the study show, however, 
that the path to a successful germline 
modification, should humanity decide to 
pursue it, may still be a long trek. 
Specifically, the desired genetic 
manipulation succeeded only in four out 
of 28 embryos, and even those embryos 
showed mosaicism, meaning that not all 2015 Elsevier Ltd All rights reserved R441
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encoded in the brain. Somehow, I now 
find myself a neuroscientist. But I still 
suffer from gaps in my knowledge. 
That is why I like collaborating.of their cells carried the change. Moreover, 
the cells had their own mind on how to 
repair the change, with a quarter of them 
using endogenous templates, while cuts 
in off-target locations were also observed. 
The high likelihood of unwanted reactions 
led the authors to conclude that the 
system is not ready for clinical application 
yet. Ironically, they backed up this 
conclusion by citing both the statements 
of concern from Lanphier and colleagues 
and from the Napa meeting, which had 
been triggered by the rumours of their 
own endeavours. 
Criticism of the publication has claimed 
that the method used was not up-to-date 
and that the paper was rushed through 
publication, with an acceptance date 
only one day after receipt. However, the 
journal has defended the review process 
and stated that the paper arrived with 
peer reviews from previous submissions 
to other journals and that it was fast-
tracked due to its high relevance.  
While the Chinese paper shows 
that designer babies are not going to 
be born soon, it has also alerted the 
world to the realisation that, once the 
technical issues are resolved, it may 
be impossible to police a global ban 
on germline modifications. Even if 
most of us don’t want to live in a world 
of genetically optimised offspring as 
described in GATTACA, the impact of 
technological progress may already be 
driving us in that direction. 
The Nuffield Council on Bioethics, 
which has already played a key role 
in shaping the UK’s policy to permit 
mitochondrial replacement therapy 
with a report published in 2012, is now 
setting up a new project to explore 
the ethical issues attached to genome 
editing. The council’s assistant director, 
Peter Mills wrote in a blog post: “The 
escape of genome editing from the 
laboratory into the public sphere — 
especially following the development of 
the CRISPR–Cas9 system — suggests 
that contained use, at least in the sense 
of reserving questions about the use 
of genome editing for researchers qua 
researchers to address, is no longer 
possible.” Pandora’s box has been cast 
wide open, and we, as a civilisation, 
now face the challenge of deciding how 
we are going to deal with its content.
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web page 
at www.michaelgross.co.ukR442 Current Biology 25, R439–R447, June Barbara  
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What turned you on to biology in the 
first place? Actually, the only biology 
class I ever took was when I was 15, 
in high school. I studied electrical 
engineering and mathematics as an 
undergraduate, then went to graduate 
school at MIT thinking I would learn 
to design computers. Once there, 
I discovered groups of engineers 
studying auditory perception, speech, 
and related areas. As a semi-serious 
musician (I play oboe and English 
horn), I was immediately seduced by 
the idea of studying hearing. Well, 
actually, not immediately. I spent a 
couple of weeks soul searching. I 
had always thought of myself as a 
hard-core engineer, doing heavy-duty 
mathematics. To switch to an area that 
was just plain fun felt wrong, as if I was 
selling out somehow. But I got over 
that. And I have been having fun ever 
since. With each step of my career, 
I’ve been drawn to looking deeper 
and deeper into how information is 
Q & A1, 2015 ©2015 Elsevier Ltd All rights reservedHow did you end up studying 
auditory attention? My career path is 
a series of happy coincidences. As a 
master’s student at MIT, I did my first 
research project, on spatial hearing, 
under the guidance of Nat Durlach, 
Steve Colburn, and Pat Zurek (three 
fantastic mentors and an all-star team 
in the world of hearing). I worked 
briefly at MIT Lincoln Laboratory as 
a hardware engineer, but decided I 
really liked pure research, so I went 
back to MIT to do my PhD in the same 
research group. My son Nick was 
born three weeks after I defended 
my thesis. I spent the next two years 
working as a part-time post-doc, 
joining the faculty at Boston University 
when my son Will was two months old. 
Because there was no anechoic 
chamber at Boston University, I 
couldn’t do the carefully controlled 
studies of sound localization I had 
been doing at MIT. So instead, like 
making the proverbial lemonade from 
lemons, I began studying how room 
acoustics affect auditory spatial cues 
and how we localize sounds in the real 
world. I was struck by how messy and 
noisy spatial auditory cues typically are 
(nothing like the textbooks suggest). 
This observation got me interested in 
the fact that spatial hearing has a big 
impact on our ability to communicate 
in everyday settings, even though 
the localization cues are unreliable, 
